Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer
Marion T. Weigel(Institute of Cancer Research), Lesley‐Ann Martin(Institute of Cancer Research)
Cited by 43
Related Papers
In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells
|BMC Cancer|2010|56
Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
|Breast Cancer Research|2012|33